SO
SGMT icon

STRS Ohio’s Sagimet Biosciences SGMT Stock Holding History

STRS Ohio’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-51,941
Closed -$281K – 2082
2024
Q1 		$281K Buy
51,941
+47,441
+1,054% +$341K ﹤0.01% 1459
2023
Q4 		$24K Buy
4,500
+3,400
+309% +$16K ﹤0.01% 1839
2023
Q3 		$9K Buy
+1,100
New +$14.6K ﹤0.01% 1905

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

STRS Ohio's SGMT Position: Q2 2024 in Review

STRS Ohio sold out of Sagimet Biosciences (SGMT) in Q2 2024, closing a stake of 51,941 shares — an estimated $281K sold.

STRS Ohio first reported a position in SGMT in Q3 2023 and held it in 3 quarters. The position peaked at $281K in Q1 2024. 82 funds tracked by Wall St. Rank hold SGMT as of Q2 2024.

  • STRS Ohio reported no remaining Sagimet Biosciences position as of Q2 2024 after selling out during the quarter.
  • STRS Ohio sold 51,941 Sagimet Biosciences shares in Q2 2024, an estimated $281K.
  • STRS Ohio first reported a position in Sagimet Biosciences in Q3 2023 and held it in 3 quarters.
  • STRS Ohio's Sagimet Biosciences position peaked at $281K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2024.

Based on STRS Ohio's 13F filing for Q2 2024, filed 5 Aug 2024.